Targeting Histone Methylation in Cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Human cancers frequently display altered epigenetic signatures driving aberrant gene expression and cellular transformation.
• Historically, epigenetic interventions focused on DNA methylation and histone acetylation.
• Recent studies highlight histone and chromatin regulators as frequently dysregulated in diverse cancer types.

Purpose of the Study:

• To present the rationale for targeting histone methylation in cancer therapy.
• To provide an update on key histone methylation targets under clinical investigation.

Main Methods:

• Review of genome-wide studies identifying dysregulated histone and chromatin regulators.
• Identification of specific histone methylation regulators as therapeutic targets.
• Summary of clinical investigations for selected targets.

Main Results:

• Histone methylation regulators represent a significant class of potential therapeutic targets in oncology.
• Key targets include histone lysine methyltransferases (e.g., enhancer of zeste homolog 2, DOT1L), protein arginine methyltransferases (e.g., protein arginine methyltransferase 5), and histone lysine demethylases (e.g., lysine-specific demethylase 1).

Conclusions:

• Targeting histone methylation pathways presents a promising strategy for cancer treatment.
• Several histone methylation regulators are actively being investigated in clinical trials for various cancers.